FDA approved it as Sunharbo on 9 November: 50 mg once daily with antiplatelets after a recent mild-to-moderate non-cardioembolic stroke or high-risk TIA. Ischemic stroke 6.2% vs 8.4% on placebo. In AF, the same-dose trial stopped early: stroke or systemic embolism 1.3% vs 0.4% on apixaban.
Key points
- Phase 2 in AF was a bleeding study: 50 mg gave 92% factor XIa inhibition at trough
- Phase 2 in stroke showed no dose-response on its primary endpoint
- Both Phase 3s tested 50 mg only; no AF indication
Our read: hitting the target beat placebo, not apixaban; against an active comparator we would not take one dose to Phase 3 on target engagement and bleeding alone.
If Phase 2 hits the target but shows no dose-response, how many doses go into Phase 3?
In detail
Stroke: better than placebo, on top of antiplatelets
Hazard ratio 0.74. FDA approval 9 November 2026, 50 mg once daily. Major bleeding similar overall, higher above 75 years and in the first 90 days.
Atrial fibrillation: worse than apixaban
Same 50 mg once daily. The trial was stopped early on the data monitoring committee's advice. Major bleeding was lower: 0.2% vs 0.7%.
Hitting the target is not beating the comparator
- Phase 2 in AF was a bleeding study: 50 mg gave 92% factor XIa inhibition at the lowest drug level, 94% at peak
- Phase 2 in stroke tested 10, 20 and 50 mg and showed no dose-response on its primary endpoint
- Against an active comparator, we would not take one dose into Phase 3 on target engagement and bleeding data alone
Sources
- fda.gov: https://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk
- Phase 3: OCEANIC-STROKE,: https://labeling.bayerhealthcare.com/html/products/pi/Sunharbo_PI.pdf
- Sharma et al., NEJM 2026, and OCEANIC-AF, Piccini et al.,: https://doi.org/10.1056/NEJMoa2513880
- NEJM 2025, Phase 2: PACIFIC-AF,: https://doi.org/10.1056/NEJMoa2407105
- )00456-1 and PACIFIC-Stroke,: https://doi.org/10.1016/S0140-6736(22
- pace-cme.org: https://pace-cme.org/news/results-prematurely-stopped-oceanic-af-trial-asundexian-af/2468011/